将mRECIST纳入Metroticket 2.0标准可改善肝移植后HCC相关死亡的预测
本研究纳入859例接受新辅助治疗后的肝移植HCC患者,按mRECIST评估移植前影像学反应。完全缓解、部分缓解/稳定和进展患者的5年HCC相关死亡率分别为3.1%、9.6%和13.4%。将mRECIST纳入Metroticket 2.0可改善预测能力,总体NRI为5.8。
要点
- 移植前mRECIST评估的完全缓解者5年HCC相关死亡率为3.1%。
- 进展者5年HCC相关死亡率为13.4%,显著高于完全缓解者。
- 将mRECIST纳入Metroticket 2.0可改善预测,总体NRI为5.8。
核心结论
- 将mRECIST纳入Metroticket 2.0框架可改善其预测能力,有助于判断新辅助治疗后肝移植候选者的适宜性。
研究设计与样本
- 纳入2000至2015年间859例接受新辅助治疗后行肝移植的患者,回顾移植前末次影像学评估并按mRECIST标准判定。
- 采用竞争风险分析,并通过基于类别的净重分类改善(NRI)分析探索影像学反应加入Metroticket 2.0的附加价值。
主要发现
- 移植前末次影像学评估中,完全缓解(CR)占41.3%,部分缓解/稳定(PR/SD)占24.9%,进展(PD)占33.8%。
- CR、PR/SD和PD患者的5年HCC相关死亡率分别为3.1%、9.6%和13.4%(p<0.001)。
- 对于PR/SD和PD患者,Log10AFP(p<0.001)以及肿瘤数目与直径之和(p<0.05)是HCC相关死亡的决定因素。
- 为使移植后5年HCC相关死亡发生率<30%,Metroticket 2.0标准在某些PR/SD和所有PD病例中受到限制。
- 该限制正确重分类了9.4%的HCC相关死亡患者,代价是3.5%未发生事件的患者被重分类,总体/净NRI为5.8。
关键数值与推荐
- 移植前mRECIST完全缓解者5年HCC相关死亡率为3.1%,部分缓解/稳定者为9.6%,进展者为13.4%(p<0.001)。
- 在PR/SD和PD患者中,Log10AFP(p<0.001)和肿瘤数目与直径之和(p<0.05)与HCC相关死亡相关。
- 为维持移植后5年HCC相关死亡发生率<30%,对部分PR/SD和所有PD病例限制Metroticket 2.0标准,总体/净NRI为5.8。
临床怎么用
- 对于接受新辅助治疗的HCC肝移植候选者,可在Metroticket 2.0框架中纳入移植前mRECIST评估的影像学反应。
- 影像学反应为PD者移植后HCC相关死亡风险较高,需结合AFP和肿瘤负荷综合判断适宜性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In the context of liver transplantation (LT) for hepatocellular carcinoma (HCC), prediction models are used to ensure that the risk of post-LT recurrence is acceptably low. However, the weighting that 'response to neoadjuvant therapies' should have in such models remains unclear. Herein, we aimed to incorporate radiological response into the Metroticket 2.0 model for post-LT prediction of "HCC-related death", to improve its clinical utility. METHODS: Data from 859 transplanted patients (2000-2015) who received neoadjuvant therapies were included. The last radiological assessment before LT was reviewed according to the modified RECIST criteria. Competing-risk analysis was applied. The added value of including radiological response into the Metroticket 2.0 was explored through category-based net reclassification improvement (NRI) analysis. RESULTS: At last radiological assessment prior to LT, complete response (CR) was diagnosed in 41.3%, partial response/stable disease (PR/SD) in 24.9% and progressive disease (PD) in 33.8% of patients. The 5-year rates of "HCC-related death" were 3.1%, 9.6% and 13.4% in those with CR, PR/SD, or PD, respectively (p <0.001). Log10AFP (p <0.001) and the sum of number and diameter of the tumour/s (p <0.05) were determinants of "HCC-related death" for PR/SD and PD patients. To maintain the post-LT 5-year incidence of "HCC-related death" <30%, the Metroticket 2.0 criteria were restricted in some cases of PR/SD and in all cases with PD, correctly reclassifying 9.4% of patients with "HCC-related death", at the expense of 3.5% of patients who did not have the event. The overall/net NRI was 5.8. CONCLUSION: Incorporating the modified RECIST criteria into the Metroticket 2.0 framework can improve its predictive ability. The additional information provided can be used to better judge the suitability of candidates for LT following neoadjuvant therapies. LAY SUMMARY: In the context of liver transplantation for patients with hepatocellular carcinoma, prediction models are used to ensure that the risk of recurrence after transplantation is acceptably low. The Metroticket 2.0 model has been proposed as an accurate predictor of "tumour-related death" after liver transplantation. In the present study, we show that its accuracy can be improved by incorporating information relating to the radiological responses of patients to neoadjuvant therapies.
引用
- Cucchetti A, Serenari M, Sposito C, et al. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol. 2020. PMID: 32201284. doi:10.1016/j.jhep.2020.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。